Incidence of Febrile Neutropenia in Korean Female Breast Cancer Patients Receiving Preoperative or Postoperative Doxorubicin/Cyclophosphamide Followed by Docetaxel Chemotherapy

PURPOSE: Doxorubicin/cyclophosphamide followed by docetaxel chemotherapy (AC-D) is an intermediate risk factor (incidence of 10%–20%) for febrile neutropenia (FN) in breast cancer. However, the reported incidence of FN while using this regimen was obtained mostly from Western breast cancer patients,...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Breast Cancer
Autori principali: Kim, Chang Gon, Sohn, Joohyuk, Chon, Hongjae, Kim, Joo Hoon, Heo, Su Jin, Cho, Hyunsoo, Kim, In Jung, Kim, Seung Il, Park, Seho, Park, Hyung Seok, Kim, Gun Min
Natura: Artigo
Lingua:Inglês
Pubblicazione: Korean Breast Cancer Society 2016
Soggetti:
Original Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4822110/
https://ncbi.nlm.nih.gov/pubmed/27064666
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4048/jbc.2016.19.1.76
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi